Research Article

EGFR-AS1 Promotes Bladder Cancer Progression by Upregulating EGFR

Anbang Wang, Aimin Jiang, Xinxin Gan, Zheng Wang, Jinming Huang, Kai Dong, Bing Liu, Linhui Wang, and Ming Chen

Department of Urology, Changzheng Hospital, Naval Medical University, Shanghai 200003, China

Correspondence should be addressed to Linhui Wang: wanglinhuicz@163.com and Ming Chen: chenming55@163.com

Received 21 October 2020; Accepted 13 December 2020; Published 28 December 2020

Academic Editor: Jingjing Gao

Copyright © 2020 Anbang Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Long noncoding RNAs play an essential role in bladder cancer progression. The role of long noncoding RNA EGFR-AS1 in bladder cancer needs further study. We used clinical specimens to analyze the relationship between EGFR-AS1 and bladder cancer patients' characteristics. The functional experiments and mechanism studies were performed using qRT-PCR, transwell assay, survival analysis, and correlation analysis. We found that high expression of EGFR-AS1 was nearly related to aggressive bladder cancer and indicated poor prognosis for patients. The functional experiments in vivo and in vitro suggested that EGFR-AS1 promoted the proliferation and invasion of bladder cancer cells. Mechanically, EGFR-AS1 promoted the expression of EGFR by inhibiting the degradation of EGFR mRNA, thereby promoting the metastasis of bladder cancer. In addition, EGFR-AS1/EGFR may be involved in the immune-related pathways of bladder cancer. These studies indicate that the EGFR-AS1/EGFR pathway may be a potential diagnostic marker and therapeutic target for bladder cancer.

1. Introduction

Bladder cancer is one of the most common malignant tumors in the urinary system, ranking fourth and seventh for male and female tumor mortality globally, respectively. GLOBOCAN statistics estimate that there are 549,400 new cases and 199 thousand bladder cancer deaths in 2018 [1]. Whether the tumor has muscular infiltrating growth is the most important indicator to judge the prognosis. Muscle invasive bladder cancer (MIBC) possesses the characteristics of rapid progress, inescapable recurrence, uncomplicated distant metastasis, high malignancy, and high mortality [2]. Cisplatin combined with gemcitabine is the first-line treatment for metastatic bladder cancer. However, the objective response rate of chemotherapy is only 48%, the median disease progression time of patients is less than six months, and the overall survival time is 13.8 months. The low response rate and drug resistance of standard chemotherapy severely limit the effectiveness of chemotherapy. The targeted therapy that has emerged in recent years as a new treatment model with a definite curative effect and better tolerance of patients has already achieved initial results in treating malignant solid tumors. Current potential targets for bladder cancer include epidermal growth factor receptor, fibroblast growth factor receptor, mTOR signaling pathway, and immune checkpoint inhibitors [3, 4]. The effectiveness and specific mechanism of action of these targets still need to be further explored to improve the effectiveness of targeted therapy for bladder cancer. Therefore, it is imperative to study the potential mechanism of bladder cancer and find new targets for intervention.

Long noncoding RNA is a newly discovered noncoding RNA (lncRNA) of more than 200 nucleotides, studied in various diseases and biology [5]. lncRNA is associated with tumorigenesis and may become a new biomarker for tumor diagnosis, prognosis, and even targeted gene therapy. However, its primary mechanism still needs further study. By searching the TCGA and GEO databases in the early stage of the research group, long noncoding RNA EGFR-AS1 closely related to renal cancer metastasis was selected. Our research group found that EGFR-AS1 maintained the stability of EGFR mRNA by binding to the RNA binding protein
HuR and promoted the proliferation and metastasis of renal cancer. The high expression of EGFR-AS1 was closely related to the poor prognosis of renal cancer patients [6]. Some recent studies have shown that EGFR-AS1 mainly plays a crucial role in cancer progression [7, 8]. Tan et al. found that EGFR-AS1 affected the sensitivity of squamous cell carcinoma to TKIs by regulating EGFR spliceosome [7]. The EGFR signaling pathway is also excessively activated in bladder cancer cells, which may directly promote the growth and metastasis of bladder cancer. Kim et al. showed that the EGFR expression level was a new prognostic indicator of disease progression for bladder cancer patients with local recurrence or metastatic MIBC [9]. However, the role of the EGFR-AS1/EGFR signaling pathway needs further research.

This study found that EGFR-AS1 was highly expressed in bladder cancer tissues and predicted poor prognosis of patients. Subsequent mechanism studies confirmed that EGFR-AS1 promoted the high expression of EGFR by maintaining its RNA stability, thereby promoting the progression of bladder cancer. Besides, EGFR-AS1 was involved in the immune-related pathways of bladder cancer. The results indicate that further studies are warranted to elucidate the complex pathway of EGFR-AS1 in bladder cancer.

2. Materials and Methods

2.1. Patient and Clinical Specimens. A total of 128 bladder cancer tissues and adjacent normal specimens were collected from postoperative bladder cancer patients at Changzheng Hospital, Naval Medical University. All tissues were frozen immediately after the operation and stored in -80-degree refrigerator. More than two pathologists confirmed all excised tissues. The pathological stage and grade of all tissues were evaluated according to the World Health Organization (WHO) criteria. All patients signed the informed consent for the study. The research project was approved by the Ethics Committee of Changzheng Hospital.

2.2. Immune Correlation Analysis. ImmLnc research and TIMER analysis were used to analyze the correlation between EGFR-AS1 and immune pathways. These two analysis tools are based on the network to analyze the difference of immune cell infiltration in different tumors (ImmLnc: http://biobigdata.hrbnu.edu.cn/ImmLnc/; TIMER: http://cistrome.dfi.harvard.edu/TIMER/).

2.3. Cell Culture and Transfection. The bladder cancer cell lines used in the experiment were all purchased from the American ATCC Cell Bank; 5637 and T24 cell lines were cultured in RPMI1640 medium (Gibco) containing 10% fetal bovine serum (HyClone). The cell culture conditions were American ATCC Cell Bank; 5637 and T24 cell lines were used in the experiment were all purchased from the American ATCC Cell Bank. The cell culture conditions were 37°C, 5% CO₂, saturated humidity incubator. We purchased the EGFR-AS1 knockdown and overexpressed lentiviruses (lv-shEGFR-AS1 and lv-oeEGFR-AS1) from Shanghai Heyuan Biotechnology and screened and verified them [6].

2.4. RNA Isolation and RT-PCR Analyses. Total RNA was extracted and separated using TRizol reagent (Invitrogen, USA). The RT-PCR experiment was performed using the ABI 7900HT Fast Real-Time PCR System (Applied Biosys-
tems, USA) and repeated three times. The expression level of RNA was calculated using β-actin as a standard internal parameter and 2⁻ΔΔCt was calculated. The RNA primer sequences are as follows: EGFR-AS1 forward, 5’- CCATCA CGTAGGCTTCTGG-3’ and reverse, 5’- GCATTCATGCAGTTTCACCTG-3’ and EGFR forward, 5’- TGGTCA AGTGCTGGATGATAAG-3’ and reverse, 5’- ACGGTA GAAGTTGGAGTCTGTA-3’. RT-PCR experiments were performed in two bladder cancer cell lines.

2.5. Cell Proliferation Test. We used the MTT method to evaluate the proliferation ability of bladder cancer cells. The treated bladder cancer cells were planted in 96-well plates, with 2 × 10⁴ cells per well. After 5 days of cell culture, the cells were treated with MTT for 4 hours, and then, the absorbance of light with a wavelength of 490 nm in a microplate reader was compared with time. OD490 value here reflects the number of viable cells. Every cell proliferation experiment was repeated three times.

2.6. Transwell Test. We used the number of cells passing through Matrigel to evaluate the migration and invasion ability of bladder cancer cells. First of all, 3 × 10⁵ cells were seeded into 24-well plates. The cells were plated in serum-free medium, and the lower chamber contained the medium and 10% fetal bovine serum. After incubation for 24 hours, the cells that did not invade the pores were carefully wiped with a cotton swab. All cells migrating from the upper part of the filter to the lower part were fixed with 4% paraformaldehyde and stained with 1% crystal violet. Then, we count and image them (magnification ×100). These measurements were made at least three times.

2.7. Statistical Analysis. In this study, SPSS Statistics software version 18 (SPSS Inc., USA) and GraphPad Prism 6 software (GraphPad Software, Inc.) were used for statistical analysis. Depending on the type of data, suitable statistical methods were selected, including t-test, variable analysis, and chi-square test. Kaplan–Meier method with the log-rank test was used to compare the prognosis of patients with different EGFR-AS1 expressions. A p value of less than 0.05 on both sides indicates statistical significance.

3. Results

3.1. EGFR-AS1 Is Related to Cancer Progression and Participated in Immune Pathways of Bladder Cancer. First, we analyzed the correlation between the EGFR-AS1 expression and clinical characteristics of bladder cancer patients. The qRT-PCR analysis found that the expression of EGFR-AS1 in bladder cancer tissues was higher than that in normal tissues. In particular, EGFR-AS1 was more expressed in muscle invasive bladder cancer (MIBC) tissues (Figure 1(a)). EGFR-AS1 was expressed higher in tumors > 4 cm than in tumors ≤ 4 cm (p < 0.001), in high-grade tumors than in low-grade tumors (p < 0.01), and in the lymph node metastasis group than in the no lymph node metastasis group (p < 0.01) (Figures 1(b)–1(e)).
According to the expression level of EGFR-AS1, 128 bladder cancer tissues were divided into the high-expression EGFR-AS1 group and low EGFR-AS1 group. High expression of EGFR-AS1 is closely related to larger tumor diameter, high grade, and lymphatic metastasis (Table 1). These results indicated that EGFR-AS1 was associated with aggressive clinical features of bladder cancer.
Immunotherapy has gradually shown a specific role in the treatment of advanced bladder cancer [10, 11]. We analyzed the correlation between EGFR-AS1 and immune pathways of bladder cancer. Using lmLnc research, we found that EGFR-AS1 was strongly correlated with the TCR signaling pathway and cytokine receptors. In addition, the results showed that EGFR-AS1 was strongly related to CD8+ T cell (Table 2). EGFR-AS1 can promote the expression of EGFR in urinary system cancer [6]. Using TIMER analysis, we identified that EGFR was significantly correlated with CD8+ T cell, neutrophil, and dendritic cell (Figure 1(f)). These results indicate that EGFR-AS1 may promote cancer progression by participating in the immune-related pathways of bladder cancer.

3.2. The Diagnostic and Prognostic Values of High EGFR-AS1 Expression in Bladder Cancer Patients. We used the ROC curve to analyze the diagnostic value of the EGFR-AS1 expression in patients with bladder cancer. The study suggested that high EGFR-AS1 expression could statistically distinguish bladder cancer and adjacent tissues, and the area under the curve (AUC) = 0.845 (95% CI: 0.761-0.908, \( p < 0.0001 \)) (Figure 2(a)). Similarly, high EGFR-AS1 expression could also discriminate the clinical stages (AUC = 0.776, \( p < 0.0001 \)) and pathological grades (AUC = 0.704, \( p < 0.0001 \)) (Figures 2(b) and 2(c)) of bladder cancer. The TCGA bladder cancer data analysis implied that the high expression of EGFR-AS1 was associated with poor prognosis of bladder cancer (Figures 2(d) and 2(e)). These results indicated that EGFR-AS1 may have diagnostic and prognostic values for bladder cancer patients.

3.3. EGFR-AS1 Facilitates the Proliferation and Invasion of Bladder Cancer Cells In Vitro. The expression of EGFR-AS1 was detected in various bladder cancer cell lines. We found that EGFR-AS1 expressed higher levels in the T24 and 5637 cell lines (Figure 3(a)). Thus, we used the 5637 and T24 cell lines to construct EGFR-AS1 overexpression and interference cell lines (lv-oeEGFR-AS1, lv-shEGFR-AS1). MTT experiments indicated that knocking down EGFR-AS1 significantly inhibited the proliferative capacity of bladder cancer cells (Figure 3(b)). The transwell experiment showed that after downregulating EGFR-AS1, the invasion ability of cell lines significantly decreased (Figure 3(c)). Correspondingly, EGFR-AS1 overexpression promoted the proliferation and invasion capacity of bladder cancer cells (Figures 3(d) and 3(e)).

3.4. Knocking down EGFR-AS1 Inhibits Bladder Cancer Growth and Metastasis In Vivo. To determine the role of EGFR-AS1 in vivo, EGFR-AS1 knockdown cell line and control group were injected into nude mice. After several weeks of observation, we found that the tumor growth on the side of the injection knockdown EGFR-AS1 was slower (Figures 4(a) and 4(b)). We detected the expression of EGFR mRNA in the transplanted tumor and found that knocking down EGFR-AS1 resulted in lower EGFR mRNA expression (Figure 4(c)). This indicates that EGFR-AS1 can promote the growth and metastasis of bladder cancer in vivo.

3.5. EGFR-AS1 Upregulates EGFR mRNA Expression by Maintaining Its Stability. EGFR-AS1 and EGFR have a certain sequence complementarity (Figure 5(a)); thus, we explore the effect of EGFR-AS1 on EGFR expression. The correlation analysis suggested EGFR-AS1 was significantly positively correlated with EGFR using the TCGA database (Figure 5(b)). We found that after knocking down EGFR-AS1, the expression of EGFR mRNA was significantly reduced (Figure 5(c)). We used actinomycin D, a transcription inhibitor, to detect the stability of EGFR mRNA. Similar to renal cancer, knocking down EGFR-AS1 significantly diminished the stability of EGFR mRNA. This effect was most obvious after 4 h (Figures 5(d)-5(g)). Previous experiments have shown that EGFR mRNA can be detected in the EGFR-AS1 pulldown product, indicating that EGFR-AS1 and EGFR have a direct binding effect [6]. These studies demonstrate that in bladder cancer cells, EGFR-AS1 can directly bind to EGFR mRNA and increase its stability.

In conclusion, our research showed that EGFR-AS1 was associated with aggressive clinical features of bladder cancer, and high expression of EGFR-AS1 predicts poor prognosis for bladder cancer patients. EGFR-AS1 enhanced the propagation and invasion of bladder cancer cells in vitro and in vivo. EGFR-AS1 promoted EGFR mRNA expression by maintaining its stability. The EGFR-AS1/EGFR pathway may be developed into diagnostic markers and potential targets of bladder cancer.

Table 1: Correlations between EGFR-AS1 expression and clinicopathological features.

| Variables                  | Low EGFR-AS1 (n = 64) | High EGFR-AS1 (n = 64) | p value |
|----------------------------|-----------------------|------------------------|---------|
| Gender                     |                       |                        | 0.283   |
| Male                       | 40                    | 34                     |         |
| Female                     | 24                    | 30                     |         |
| Age                        |                       |                        | 0.592   |
| \( \leq 60 \)              | 35                    | 38                     |         |
| \( > 60 \)                 | 29                    | 26                     |         |
| Tumor size (cm)            |                       |                        | 0.050   |
| \( \leq 3 \) cm            | 41                    | 30                     |         |
| \( > 3 \) cm               | 23                    | 34                     |         |
| Pathology stage            |                       |                        | 0.013*  |
| Ta-T1                      | 43                    | 29                     |         |
| T2-T3                      | 21                    | 35                     |         |
| Grade                      |                       |                        | 0.021*  |
| G1-G2                      | 36                    | 23                     |         |
| G3                         | 28                    | 41                     |         |
| Lymphatic metastasis       |                       |                        | 0.023+  |
| No                         | 54                    | 43                     |         |
| Yes                        | 10                    | 21                     |         |
| Recurrence                 |                       |                        | 0.042+  |
| No                         | 47                    | 36                     |         |
| Yes                        | 17                    | 28                     |         |

* \( p < 0.05 \) were considered statistically significant.
Table 2: Correlation analysis between EGFR-AS1 and immune pathways in bladder cancer.

| IncRNA symbol | Immune pathway/cell                          | \( p \) value | Marker gene number |
|---------------|---------------------------------------------|---------------|-------------------|
| EGFR-AS1      | TCR signaling pathway                       | 0.002*        | 20                |
| EGFR-AS1      | Cytokine receptors                          | 0.006*        | 66                |
| EGFR-AS1      | BCR signaling pathway                       | 0.06          | 11                |
| EGFR-AS1      | Antigen processing and presentation         | 0.079         | 25                |
| EGFR-AS1      | Interleukin receptor                        | 0.079         | 19                |
| EGFR-AS1      | Natural killer cell cytotoxicity            | 0.092         | 14                |
| EGFR-AS1      | CD8_Tcell                                   | 0.025*        | /                 |
| EGFR-AS1      | Neutrophil                                  | 0.136         | /                 |
| EGFR-AS1      | Dendritic                                   | 0.135         | /                 |
| EGFR-AS1      | B_cell                                      | 0.359         | /                 |
| EGFR-AS1      | CD4_Tcell                                   | 0.409         | /                 |
| EGFR-AS1      | Macrophage                                  | 0.855         | /                 |

*\( p \) values < 0.05 were considered statistically significant.

![ROC curve analysis](a)

![ROC curve analysis](b)

![ROC curve analysis](c)

![Kaplan-Meier analysis](d)

![Kaplan-Meier analysis](e)

**Figure 2:** The diagnostic and prognostic values of the EGFR-AS1 expression in bladder cancer. (a) ROC curve analysis showed that EGFR-AS1 could efficiently distinguish bladder cancer from a normal individual. The area under curve (AUC) was 0.845 (\( p < 0.0001 \)). ROC curve analysis towards the expression levels of EGFR-AS1 in bladder cancer subgroups against tumor stage (b) and tumor grade (c). Kaplan–Meier analysis of overall survival rate (d) and disease-free survival (e) of bladder cancer patients with high or low EGFR-AS1 expression in the TCGA database (\( p = 0.0011 \), \( p = 0.025 \)).
EGFR-AS1

(a) 

(b) 

(c) 

(d) 

Figure 3: Continued.
4. Discussion

LncRNA EGFR-AS1 was selected from big data of renal cancer. We found that EGFR-AS1 promoted renal cancer progression. EGFR-AS1 is closely related to EGFR and is a splicing by-product. Many studies have shown that EGFR played an essential role in bladder cancer [9, 12]. Therefore, we tried to study the role of EGFR-AS1 in bladder cancer. The experiments in vitro and in vivo showed that EGFR-AS1 enhanced the metastatic capacity of bladder cancer cells. Clinical data analysis also demonstrated that EGFR-AS1 was closely related to the aggressive clinical characteristics and poor prognosis of bladder cancer. These studies indicated the promoting effect of EGFR-AS1 on bladder cancer.

Many studies have shown the crucial effect of EGFR on bladder cancer. Gao et al. found that TRIP13 could directly bind to EGFR and regulate the EGFR signaling pathway to promote the formation of bladder cancer [13]. The DDX31/Mutant-p53/EGFR pathway promoted the metastasis ability of muscle invasive bladder cancer [12]. Peng et al.' research showed that metformin and gefitinib could jointly inhibit the growth of bladder cancer through the AMPK and EGFR pathways, providing a new solution for postoperative infusion chemotherapy for bladder cancer [14]. Moreover, similar to renal cancer, our research indicated that EGFR-AS1 could also promote the stability of EGFR mRNA, upregulate EGFR expression, and thereby promote the metastasis of bladder cancer. Tan et al. found that the use of locked nucleic acids to inhibit EGFR-AS1 expression in vivo can inhibit the progression of squamous cell carcinoma [7]. The strategy of targeting EGFR-AS1 based on RNA interference technology has been clinically tested [15]. At present, EGFR inhibitors have not yet been used clinically in bladder cancer. The exploration of their
Upstream and downstream and joint inhibitors may be a good direction. For example, bladder cancer’s growth and metastasis may be repressed by jointly inhibiting the EGFR-AS1/EGFR pathway.

In recent years, immunotherapy has become a new possible direction for the treatment of bladder cancer. We also analyzed the correlation between EGFR-AS1 and immune pathways of bladder cancer and found that EGFR-AS1 was significantly correlated with the TCR signaling pathway and cytokine receptors. The TCR signaling pathway is an important pathway for the human body to play an antitumor effect.

The study also found the close relation of EGFR-AS1 and CD8_T cell, indicating that EGFR-AS1 may be responsible for the activation of the immune recognition signaling pathway in bladder cancer.

5. Conclusion

In conclusion, our study indicated that EGFR-AS1 enhanced the aggressive characteristics of bladder cancer and predicts poor prognosis. Mechanistically, EGFR-AS1 mainly promotes the expression of EGFR by maintaining the stability of EGFR mRNA and then promotes the metastasis of bladder cancer. Our study indicates that the EGFR-AS1/EGFR pathway can be used as a diagnostic marker and potential target for bladder cancer.
Data Availability

The data used to support the findings of this study are included within the article.

Conflicts of Interest

The authors declare no conflicts of interest.

Authors’ Contributions

Anbang Wang, Aimin Jiang, Xinxin Gan, and Zheng Wang equally contributed to this study.

Acknowledgments

This work was supported by grants from the National Natural Science Foundation of China (grant # 81730073, 81902560).

References

[1] R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2018,” CA: a Cancer Journal for Clinicians, vol. 68, no. 1, pp. 7–30, 2018.
[2] M. Abufaraj, K. Gust, M. Moschini et al., “Management of muscle invasive, locally advanced and metastatic urothelial carcinoma of the bladder: a literature review with emphasis on the role of surgery,” Translational Andrology & Urology, vol. 5, no. 5, pp. 735–744, 2016.
[3] N. J. Choudhury, A. Campanile, T. Antic et al., “Afatinib activity in platinum-refractory metastatic urothelial carcinoma in patients with ERBB alterations,” Journal of Clinical Oncology, vol. 34, no. 18, pp. 2165–2171, 2016.
[4] T. Powles, M. D. Galsky, D. Castellano et al., “A phase 3 study of first-line durvalumab (MEDI4736) ± tremelimumab versus standard of care (SoC) chemotherapy (CT) in patients (pts) with unresectable Stage IV urothelial bladder cancer (UBC): DANUBE,” Journal of Clinical Oncology, vol. 34, article TPS4574, supplement 15, 2016.
[5] A. M. Schmitt and H. Y. Chang, “Long noncoding RNAs in cancer pathways,” Cancer Cell, vol. 29, no. 4, pp. 452–463, 2016.
[6] A. Wang, Y. Bao, Z. Wu et al., “Long noncoding RNA EGFR-AS1 promotes cell growth and metastasis via affecting HuR mediated mRNA stability of EGFR in renal cancer,” Cell Death & Disease, vol. 10, no. 3, p. 154, 2019.
[7] D. S. W. Tan, F. T. Chong, H. S. Leong et al., “Long noncoding RNA EGFR-AS1 mediates epidermal growth factor receptor addiction and modulates treatment response in squamous cell carcinoma,” Nature Medicine, vol. 23, no. 10, pp. 1167–1175, 2017.
[8] Z. Q. Dong, Z. Y. Guo, and J. Xie, “The lncRNA EGFR-AS1 is linked to migration, invasion and apoptosis in glioma cells by targeting miR-133b/RACK1,” Biomedicine & Pharmacotherapy, vol. 118, p. 109292, 2019.
[9] W. T. Kim, J. Kim, C. Yan et al., “S100A9 and EGFR gene signatures predict disease progression in muscle invasive bladder cancer patients after chemotherapy,” Annals of Oncology, vol. 25, no. 5, pp. 974–979, 2014.
[10] P. Sharma, A. Siefker-Radtke, F. de Braud et al., “Nivolumab alone and with Ipilimumab in previously treated metastatic urothelial carcinoma: CheckMate 032 nivolumab 1 mg/kg plus ipilimumab 3 mg/kg expansion cohort results,” Journal of Clinical Oncology, vol. 37, no. 19, pp. 1608–1616, 2019.
[11] T. Powles, I. Durán, M. S. van der Heijden et al., “Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial,” Lancet, vol. 391, no. 10122, pp. 748–757, 2018.
[12] K. Daizumoto, T. Yoshimaru, Y. Matsushita et al., “A DDX31/mutant-p53/EGFR Axis promotes multistep progression of muscle-invasive bladder cancer,” Cancer Research, vol. 78, no. 9, pp. 2233–2247, 2018.
[13] Y. Gao, S. Liu, Q. Guo et al., “Increased expression of TRIP13 drives the tumorigenesis of bladder cancer in association with the EGFR signaling pathway,” International Journal of Biological Sciences, vol. 15, no. 7, pp. 1488–1499, 2019.
[14] M. Peng, Y. Huang, T. Tao et al., “Metformin and gefitinib cooperate to inhibit bladder cancer growth via both AMPK and EGFR pathways joining at Akt and Erk,” Scientific Reports, vol. 6, no. 1, p. 28611, 2016.
[15] T. Zhou, Y. Kim, and A. R. Macleod, “Targeting long noncoding RNA with antisense oligonucleotide technology as cancer therapeutics,” Methods in Molecular Biology, vol. 1402, p. 199, 2016.